



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## (R)-MG132

**Catalog #:** 27226

**Lot #:** 190206


**Size:** 1 mg

**Structure:**

**CAS Registry #:** 1211877-36-9

**Purity:** ≥98%

**Chemical Formula:** C<sub>26</sub>H<sub>41</sub>N<sub>3</sub>O<sub>5</sub>



**Molecular Weight:** 475.6

**Description:** (*R*)-MG132 is a potent, cell permeable and reversible inhibitor of proteasomes. It can inhibit proteasome activity in lysates of J558L multiple myeloma cells and EMT6 breast cancer cells. In comparison to (*S*)-MG132, the (*R*)-MG132 stereoisomer is a more effective inhibitor of chymotrypsin-like (ChTL), trypsin-like (TL), and peptidylglutamyl peptide hydrolyzing proteasome (PGPH) activities.

**Appearance:** A crystalline solid

**Solubility:** Soluble in ethanol, DMSO and DMF, purged with an inert gas. Solubility in these solvents is approximately 25 mg/ml. Do not store aqueous solutions for more than one day.

**Biological Activity:** (*R*)-MG132 inhibits ChTL, TL and PGPH with IC<sub>50</sub> values of 0.22 μM, 34.4 μM, and 2.95 μM, respectively.

**Storage/Stability:** Store at or below -20°C for up to two years.

**Quality Control:** The purity was determined by HPLC analysis.

### Reference(s):

1. Lee, D.H., *et al.*, *Trends Cell Biol.* 1998;**8**:397-403
2. Elliot, P.J., *et al.*, *J. Mol. Med.* 2003;**81**:235-245
3. Mroczkiewicz, M., *et al.*, *J. Med. Chem.* 2010;**53**:1509-1518.